Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab plus topical corticosteroids for moderate-to-severe atopic dermatitis
NL-OMON46483Phase 3Active, not recruiting
- Sponsor
- TFS HealthScience
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Tralokinumab + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoints: Investigator's Global Assessment response and EASI75 response. Started Aug 2018; status: active, not recruiting.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON46483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46483.